Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Eugene, OR
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Eugene, OR
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Ephrata, PA
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Ephrata, PA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Langhorne, PA
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Langhorne, PA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Scranton, PA
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Scranton, PA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Charleston, SC
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Florence, SC
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Florence, SC
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Sumter, SC
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Sumter, SC
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Cookeville, TN
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Cookeville, TN
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Nashville, TN
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Amarillo, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Arlington, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Beaumont, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Beaumont, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Bedford, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Carrollton, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Dallas, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Garland, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Garland, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Lewisville, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Lewisville, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Mesquite, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Paris, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Paris, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Round Rock, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Southlake, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Southlake, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Sugar Land, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Waco, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Waco, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Webster, TX
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Christiansburg, VA
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Christiansburg, VA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Seattle, WA
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Oral Calcitriol With Ketoconazole in CRPC
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone
Status: Enrolling
Updated:  2/28/2018
Inova Schar Cancer Institute
mi
from
Fairfax, VA
Oral Calcitriol With Ketoconazole in CRPC
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone
Status: Enrolling
Updated: 2/28/2018
Inova Schar Cancer Institute
mi
from
Fairfax, VA
Click here to add this to my saved trials
STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)
STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)
STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
Richard Finn, M.D.
mi
from
Los Angeles, CA
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
Richard Finn, M.D.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
Rhode Island Hospital
mi
from
Providence, RI
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
University of Virginia Health System
mi
from
Charlottesville, VA
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
Local Institution
mi
from
Capital Federal,
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated:  3/1/2018
Montefiore Medical Center
mi
from
Bronx, NY
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Status: Enrolling
Updated: 3/1/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Status: Enrolling
Updated:  3/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Status: Enrolling
Updated: 3/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer
Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer
Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
Pilot Study of Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
Status: Enrolling
Updated:  3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
Pilot Study of Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
Status: Enrolling
Updated: 3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pembrolizumab in Treating Patients With Malignant Mesothelioma
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Status: Enrolling
Updated:  3/1/2018
University of Chicago
mi
from
Chicago, IL
Pembrolizumab in Treating Patients With Malignant Mesothelioma
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Status: Enrolling
Updated: 3/1/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Afatinib Genomic Landscape
Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib
Status: Enrolling
Updated:  3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Afatinib Genomic Landscape
Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib
Status: Enrolling
Updated: 3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Genomic Landscape of Ceritinib
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Status: Enrolling
Updated:  3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Genomic Landscape of Ceritinib
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Status: Enrolling
Updated: 3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent RCC
Status: Enrolling
Updated:  3/1/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent RCC
Status: Enrolling
Updated: 3/1/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials